23
Jul
Blog
20
Jul
PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced complete enrollment of SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica. SP-102 has received Fast Track status from the FDA.
07
Jul
Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over the last decade, she has...
06
Jul
Ms. Czerepak has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. She most recently served as EVP and Chief Financial Officer of BeyondSpring Inc., a...
01
Jun
17
May
02
May
09
Apr
Palo Alto, California, April 9, 2021 — Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for...
31
Mar
08
Mar